Comparison of the inhibitory profiles of itraconazole and cimetidine in cytochrome P450 3A4 genetic variants

Drug Metabolism and Disposition

Volumn 39, Issue 4, 2011, Pages 724-728

  Akiyoshi, Takeshi ^a   Saito, Takashi ^a   Murase, Saori ^a   Miyazaki, Mitsue ^b   Murayama, Norie ^c   Yamazaki, Hiroshi ^c   Guengerich, F Peter ^d   Nakamura, Katsunori ^b,e   Yamamoto, Koujirou ^b   Ohtani, Hisakazu ^a  

^a KEIO UNIVERSITY   (Japan)

^b GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e SHINSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; CYTOCHROME P450 3A4; ITRACONAZOLE; TESTOSTERONE;

ARTICLE; CHEMICAL REACTION KINETICS; DRUG INTERACTION; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC VARIABILITY; MOLECULAR DOCKING; PRIORITY JOURNAL; TESTOSTERONE METABOLISM; WILD TYPE;

14-ALPHA DEMETHYLASE INHIBITORS; ANDROGENS; CIMETIDINE; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; ENZYME INHIBITORS; GENETIC VARIATION; HEME; HUMANS; HYDROXYTESTOSTERONES; ITRACONAZOLE; RECOMBINANT PROTEINS; TESTOSTERONE;

EID: 79952848727     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.036780     Document Type: Article

References (28)

1. Austin RP, Barton P, Cockroft SL, Wenlock MC, and Riley RJ (2002) The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab Dispos 30:1497-1503.
2. Austin RP, Barton P, Mohmed S, and Riley RJ (2005) The binding of drugs to hepatocytes and its relationship to physicochemical properties. Drug Metab Dispos 33:419-425.
3. Busby WF Jr, Ackermann JM, and Crespi CL (1999) Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450. Drug Metab Dispos 27:246-249. (Pubitemid 29072079)
4. Chauret N, Gauthier A, and Nicoll-Griffith DA (1998) Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab Dispos 26:1-4. (Pubitemid 28071316)
5. Easterbrook J, Lu C, Sakai Y, and Li AP (2001) Effects of organic solvents on the activities of cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes. Drug Metab Dispos 29:141-144. (Pubitemid 32112927)
6. Eiselt R, Domanski TL, Zibat A, Mueller R, Presecan-Siedel E, Hustert E, Zanger UM, Brockmoller J, Klenk HP, Meyer UA, et al. (2001) Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 11:447-458. (Pubitemid 32656585)
7. Fukushima-Uesaka H, Saito Y, Watanabe H, Shiseki K, Saeki M, Nakamura T, Kurose K, Sai K, Komamura K, Ueno K, et al. (2004) Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum Mutat 23:100.
8. Galetin A, Ito K, Hallifax D, and Houston JB (2005) CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions. J Pharmacol Exp Ther 314:180-190. (Pubitemid 41058254)
9. Guengerich FP (1999) Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1-17.
10. Guengerich FP (2008) Cytochrome P450 and chemical toxicology. Chem Res Toxicol 21:70-83.
11. Ishigam M, Uchiyama M, Kondo T, Iwabuchi H, Inoue S, Takasaki W, Ikeda T, Komai T, Ito K, and Sugiyama Y (2001) Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and prediction of in vivo drug-drug interactions. Pharm Res 18:622-631. (Pubitemid 32595790)
12. Isoherranen N, Kunze KL, Allen KE, Nelson WL, and Thummel KE (2004) Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos 32:1121-1131. (Pubitemid 39287586)
13. Kang YS, Park SY, Yim CH, Kwak HS, Gajendrarao P, Krishnamoorthy N, Yun SC, Lee KW, and Han KO (2009) The CYP3A4*18 genotype in the cytochrome P450 3A4 gene, a rapid metabolizer of sex steroids, is associated with low bone mineral density. Clin Pharmacol Ther 85:312-318.
14. Kriegl JM, Arnhold T, Beck B, and Fox T (2005) A support vector machine approach to classify human cytochrome P450 3A4 inhibitors. J Comput Aided Mol Des 19:189-201. (Pubitemid 40974006)
15. Kumar V, Wahlstrom JL, Rock DA, Warren CJ, Gorman LA, and Tracy TS (2006) CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles. Drug Metab Dispos 34:1966-1975. (Pubitemid 44837757)
16. Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, Strom S, Zhang J, and Schuetz EG (2002) Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 12:121-132. (Pubitemid 34298916)
17. Miyazaki M, Nakamura K, Fujita Y, Guengerich FP, Horiuchi R, and Yamamoto K (2008) Defective activity of recombinant cytochromes P450 3A4.2 and 3A4.16 in oxidation of midazolam, nifedipine, and testosterone. Drug Metab Dispos 36:2287-2291.
18. Murayama N, Nakamura T, Saeki M, Soyama A, Saito Y, Sai K, Ishida S, Nakajima O, Itoda M, Ohno Y, et al. (2002) CYP3A4 gene polymorphisms influence testosterone 6β-hydroxylation. Drug Metab Pharmacokinet 17:150-156.
19. Okada Y, Murayama N, Yanagida C, Shimizu M, Guengerich FP, and Yamazaki H (2009) Drug interactions of thalidomide with midazolam and cyclosporine A: heterotropic cooperativity of human cytochrome P450 3A5. Drug Metab Dispos 37:18-23.
20. Park H, Lee S, and Suh J (2005) Structural and dynamical basis of broad substrate specificity, catalytic mechanism, and inhibition of cytochrome P450 3A4. J Am Chem Soc 127:13634-13642. (Pubitemid 41401217)
21. Sata F, Sapone A, Elizondo G, Stocker P, Miller VP, Zheng W, Raunio H, Crespi CL, and Gonzalez FJ (2000) CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 67:48-56. (Pubitemid 30078387)
22. Shimada T, Tanaka K, Takenaka S, Murayama N, Martin MV, Foroozesh MK, Yamazaki H, Guengerich FP, and Komori M (2010) Structure-function relationships of inhibition of human cytochromes P450 1A1, 1A2, 1B1, 2C9, and 3A4 by 33 flavonoid derivatives. Chem Res Toxicol 23:1921-1935.
23. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423. (Pubitemid 24229655)
24. Teixeira VH, Ribeiro V, and Martel PJ (2010) Analysis of binding modes of ligands to multiple conformations of CYP3A4. Biochim Biophys Acta 1804:2036-2045.
25. Unwalla RJ, Cross JB, Salaniwal S, Shilling AD, Leung L, Kao J, and Humblet C (2010) Using a homology model of cytochrome P450 2D6 to predict substrate site of metabolism. J Comput Aided Mol Des 24:237-256.
26. Williams PA, Cosme J, Vinkovic DM, Ward A, Angove HC, Day PJ, Vonrhein C, Tickle IJ, and Jhoti H (2004) Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science 305:683-686. (Pubitemid 39006760)
27. Yano JK, Wester MR, Schoch GA, Griffin KJ, Stout CD, and Johnson EF (2004) The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-A resolution. J Biol Chem 279:38091-38094. (Pubitemid 39295952)
28. Zhou SF, Xue CC, Yu XQ, Li C, and Wang G (2007) Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 29:687-710. (Pubitemid 350190847)